We are currently waiting for the results of several trials including EORTC 1325 which is
investigating pembrolizumab, a PD - 1 checkpoint blocking antibody, compared to placebo in the adjuvant setting.»
Not exact matches
KEYNOTE - 024
investigated the efficacy of
pembrolizumab compared to standard of care with platinum - based chemotherapy in untreated patients with advanced NSCLC and high PD - L1 expression (defined as expression in at least 50 % of tumour cells).
Merck's anti-PD-1 drug
pembrolizumab (MK - 3475) is currently being
investigated in a large a phase I trial for patients with metastatic melanoma and lung cancer.